Rexahn Pharma (RNN) Tops Q2 EPS by 1c

Rexahn Pharma (NYSE: RNN) reported Q2 EPS of ($0.01), $0.01 better than the analyst estimate of ($0.02).

Cash Position - Rexahn's cash and investments totaled approximately $19.4 million as of June 30, 2016, compared to approximately $23.4 million as of December 31, 2015. The decrease in cash and investments during this six month period was due to approximately $8.6 million of cash used in operating activities, offset by $4.6 million of proceeds received from a registered direct offering in March 2016. Rexahn expects that its current cash and investments will be sufficient to fund the company's cash flow requirements for its current activities into the second half of 2017.

For earnings history and earnings-related data on Rexahn Pharma (RNN) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• AXIL Brands (AXIL) Tops Q4 EPS by 4c
• Jack Henry (JKHY) Tops Q4 EPS by 13c